Literature DB >> 23149017

Analyzing titers of antibodies against bacterial and viral antigens, and bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan.

Chi-Yu Wu1, Hsiu-Chi Wang, Kun-Teng Wang, Daniel Yang-Chih Shih, Chi-Fang Lo, Der-Yuan Wang.   

Abstract

Intravenous immunoglobulin (IVIG) manufactured from human plasma contains IgG as the primary ingredient, and is used for indications such as immunodeficiency syndrome. Available IVIGs in Taiwan are either manufactured from Taiwanese or North American plasma. The effectiveness of the national immunization program of Taiwan can be evaluated by analyzing and comparing IVIG antibody titers that are induced through the corresponding vaccines (tetanus, diphtheria, and pertussis, measles, rubella, hepatitis A, hepatitis B and varicella). Both enzyme-linked immunosorbent assay (ELISA) and the in vitro neutralization test demonstrated that all IVIGs provide adequate clinical protection against diphtheria and tetanus toxins. ELISA results further revealed that plasma of Taiwanese subjects contains higher levels of pertussis toxin and filamentous hemagglutinin antibodies, when compared to foreign IVIGs. This may be related to the later adoption of acellular pertussis vaccine in Taiwan. Antibodies titers against measles, rubella, hepatitis A, and varicella-zoster virus were otherwise low. Low titers of hepatitis B surface antigen antibodies are present in Taiwanese plasma IVIG, indicating immune memory decline or loss. In conclusion, our results show that Taiwanese IVIG contains varying titers of vaccine-induced antibodies, and serves as a guide for future amendments to Taiwan's immunization program.
Copyright © 2013 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149017     DOI: 10.1016/j.biologicals.2012.10.003

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

1.  Rubella antibodies in Australian immunoglobulin products.

Authors:  Megan K Young; Joseph Bertolini; Pushpa Kotharu; Darryl Maher; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

2.  Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.

Authors:  Isaak Quast; Christian W Keller; Patrick Weber; Christoph Schneider; Stephan von Gunten; Jan D Lünemann
Journal:  J Neuroinflammation       Date:  2016-02-18       Impact factor: 8.322

3.  Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.

Authors:  Soyoung Lee; Han Wool Kim; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

4.  Characterization of antibodies in human immunoglobulin products from different regions worldwide.

Authors:  Alexandra Serra; Núria Marzo; Berta Pons; Pau Maduell; Maite López; Salvador Grancha
Journal:  Int J Infect Dis       Date:  2021-01-29       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.